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CLINICAL RESEARCH ARTICLE
Associations between oxytocin and vasopressin concentrations, traumatic 
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comparisons, correlations, and courses during an internet-based 
cognitive-behavioural treatment
Sinha Engel a, Sarah Schumacher a, Helen Niemeyera, Annika Kuestera, Sebastian Burchert a, 
Hannah Klusmanna, Heinrich Raub, Gerd-Dieter Willmundb and Christine Knaevelsrud a
aDivision of Clinical Psychological Intervention, Freie Universität Berlin, Berlin, Germany; bDepartment for Military Mental Health, 
German Armed Forces, Military Hospital Berlin, Berlin, Germany
ABSTRACT
Background: Posttraumatic stress disorder (PTSD) is characterized by impairments in extinc-
tion learning and social behaviour, which are targeted by trauma-focused cognitive beha-
vioural treatment (TF-CBT). The biological underpinnings of TF-CBT can be better 
understood by adding biomarkers to the clinical evaluation of interventions. Due to their 
involvement in social functioning and fear processing, oxytocin and arginine vasopressin 
might be informative biomarkers for TF-CBT, but to date, this has never been tested.
Objective: To differentiate the impact of traumatic event exposure and PTSD symptoms on 
blood oxytocin and vasopressin concentrations. Further, to describe courses of PTSD symp-
toms, oxytocin and vasopressin during an internet-based TF-CBT and explore interactions 
between these parameters.
Method: We compared oxytocin and vasopressin between three groups of active and 
former male service members of the German Armed Forces (n = 100): PTSD patients 
(n = 39), deployed healthy controls who experienced a deployment-related traumatic 
event (n = 33) and non-deployed healthy controls who never experienced a traumatic 
event (n = 28). PTSD patients underwent a 5-week internet-based TF-CBT. We correlated 
PTSD symptoms with oxytocin and vasopressin before treatment onset. Further, we ana-
lysed courses of PTSD symptoms, oxytocin and vasopressin from pre- to post-treatment and 
3 months follow-up, as well as interactions between the three parameters.
Results: Oxytocin and vasopressin did not differ between the groups and were unrelated to 
PTSD symptoms. PTSD symptoms were highly stable over time, whereas the endocrine 
parameters were not, and they also did not change in mean. Oxytocin and vasopressin 
were not associated with PTSD symptoms longitudinally.
Conclusions: Mainly due to their insufficient intraindividual stability, single measurements 
of endogenous oxytocin and vasopressin concentrations are not informative biomarkers for 
TF-CBT. We discuss how the stability of these biomarkers might be increased and how they 
could be better related to the specific impairments targeted by TF-CBT.
Asociaciones entre concentraciones de oxitocina y vasopresina, 
exposición a eventos traumáticos y síntomas del trastorno de estrés 
postraumático: comparaciones grupales, correlaciones y cursos dur-
ante un tratamiento cognitivo-conductual basado en Internet
Antecedentes: El trastorno de estrés postraumático (TEPT) se caracteriza por deficiencias en 
el aprendizaje de extinción y el comportamiento social, que son el objetivo del tratamiento 
cognitivo conductual centrado en el trauma (TF-CBT). Los fundamentos biológicos de TF- 
CBT se pueden entender mejor agregando biomarcadores a la evaluación clínica de las 
intervenciones. Debido a su participación en el funcionamiento social y el procesamiento 
del miedo, la oxitocina y la arginina vasopresina podrían ser biomarcadores informativos 
para la TF-CBT, pero hasta la fecha, esto nunca se ha probado.
Objetivo: Diferenciar el impacto de la exposición a un evento traumático y los síntomas del 
TEPT en las concentraciones de oxitocina y vasopresina en la sangre. Además, para describir 
la evolución de los síntomas del TEPT, la oxitocina y la vasopresina durante una TF-CBT 
basada en Internet y explorar las interacciones entre estos parámetros.
Método: Comparamos la oxitocina y la vasopresina entre tres grupos de militares activos 
y ex militares de las Fuerzas Armadas Alemanas (n = 100): pacientes con TEPT (n = 39), 
controles sanos desplegados que experimentaron un evento traumático relacionado con el 
despliegue (n = 33) y controles sanos no desplegados que nunca experimentaron un evento 
traumático (n = 28). Los pacientes con TEPT se sometieron a una TF-CBT basada en Internet
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durante 5 semanas. Correlacionamos los síntomas del TEPT con la oxitocina y la vasopresina 
antes del inicio del tratamiento. Además, analizamos la evolución de los síntomas del TEPT, 
la oxitocina y la vasopresina antes y después del tratamiento y el seguimiento de 3 meses, 
así como las interacciones entre los tres parámetros.
Resultados: La oxitocina y la vasopresina no difirieron entre los grupos y no se relacionaron con 
los síntomas del TEPT. Los síntomas del TEPT fueron muy estables en el tiempo, mientras que los 
parámetros endocrinos no lo fueron, y tampoco cambiaron en la media. La oxitocina y la 
vasopresina no se asociaron con los síntomas del TEPT de forma longitudinal.
Conclusiones: Principalmente debido a su estabilidad intraindividual insuficiente, las med-
iciones únicas de las concentraciones de oxitocina y vasopresina endógenas no son bio-
marcadores informativos para TF-CBT. Discutimos cómo podría aumentarse la estabilidad de 
estos biomarcadores y cómo podrían relacionarse mejor con las deficiencias específicas a las 





更好地理解 TF-CBT 的生物学基础。由于催产素和精氨酸加压素可能参与社交功能和恐惧 
处理，因此它们可能是 TF-CBT 的信息生物标志物，但至今尚未检验。
目的：区分创伤事件暴露和 PTSD 症状对血液中催产素和加压素浓度的影响。此外，为了 
描述基于互联网的 TF-CBT 期间 PTSD 症状、催产素和加压素的过程，并探讨这些参数之 
间的相互作用。
方法：我们比较了德国武装部队三组现役和前役男性军人中的催产素和加压素（n = 100) ： 
PTSD患者（n = 39）、经历了部署相关创伤事件的已部署健康对照者（n = 33）以及从未经 
历过创伤事件的未部署健康对照组（n = 28）。 PTSD 患者接受了为期5周基于互联网的 TF- 
CBT。在治疗开始之前，我们确定了 PTSD 症状与催产素和加压素的相关。此外，我们分析 
了从治疗前、后以及随访 3 个月时的 PTSD 症状、催产素和加压素的过程，以及这三个参数 
之间的相互作用。
结果：组间催产素和加压素没有差异，并且与 PTSD 症状无关。 PTSD 症状随时间高度稳 






Posttraumatic stress disorder (PTSD) is a burdensome 
disease that causes severe impairments in individuals’ 
lives. PTSD can develop in response to a traumatic 
event, that is, exposure to actual or threatened death, 
serious injury or sexual violence, and includes symp-
toms such as intrusions, avoidance, negative alterations 
in cognition and mood, as well as marked alterations in 
arousal and reactivity (American Psychiatric 
Association et al., 2013). Globally, PTSD lifetime pre-
valence rates range from 1.3 to 8.9%, depending on 
country-specific, but also individual risk factors 
(Atwoli, Stein, Koenen, & McLaughlin, 2015). Among 
the latter, belonging to professional groups character-
ized by frequent and severe traumatic event exposure, 
such as rescue workers (Berger et al., 2012), war repor-
ters (Feinstein, Owen, & Blair, 2002) or soldiers (Hoge 
et al., 2004; Wittchen et al., 2012) increases PTSD risk. 
Furthermore, social factors, such as exposure to an 
interpersonal traumatic event (Shalev et al., 2019), par-
ticularly sexual (Schumm, Briggs-Phillips, & Hobfoll, 
2006; Tolin & Foa, 2006) or intimate partner violence 
(Forbes et al., 2014), as well as low perceived social 
support after traumatic event exposure (Andrews, 
Brewin, & Rose, 2003; Brewin, Andrews, & Valentine, 
2000; Schumm, Briggs-Phillips, & Hobfoll, 2006; Ozer, 
Best, Lipsey, & Weiss, 2003) increase individuals’ risk to 
develop PTSD.
From a neurocognitive perspective, PTSD develop-
ment and maintenance can be explained by deficient 
extinction learning (for overviews, see Parsons & 
Ressler, 2013; Zuj, Palmer, Lommen, & Felmingham, 
2016). Fear learning represents a normal process after 
traumatic event exposure that can be regarded as adap-
tive. Learning that certain cues or contexts that co- 
occurred with a traumatic event might indicate danger 
helps individuals to avoid dangerous situations in the 
future. However, subsequent impaired extinction learn-
ing can be regarded as a maladaptive process after 
traumatic event exposure, as fear responses to trauma 
reminders are maintained even after repeatedly experi-
encing that the reminders no longer co-occur with the 
anticipated event (Zuj & Norrholm, 2019). Several stu-
dies reported deficient extinction learning in PTSD, as 
reflected in increased general and differential fear 
responses during extinction acquisition (Orr et al., 
2000; Peri, Ben-Shakhar, Orr, & Shalev, 2000; Steiger, 
Nees, Wicking, Lang, & Flor, 2015; Wessa & Flor, 2007), 
as well as impaired extinction recall (Garfinkel et al., 
2014; Milad et al., 2008, 2009).
2 S. ENGEL ET AL.
Extinction learning is promoted in trauma-focused 
cognitive behavioural therapy (TF-CBT), which is one of 
the gold standard PTSD treatments (National Institute of 
Clinical Excellence, 2018). TF-CBT encompasses pro-
grammes such as cognitive processing therapy (; Monson 
et al., 2006; Resick & Schnicke, 1993), (prolonged) expo-
sure therapy (Foa et al., 2005; Foa, Rothbaum, Riggs, & 
Murdock, 1991) or narrative exposure therapy (Hermenau 
et al., 2013; Neuner et al., 2004). They aim at promoting the 
adaptive processing of traumatic memories which is, 
among other techniques, achieved by psychotherapist- 
guided exposure. During exposure, PTSD patients repeat-
edly confront themselves with their traumatic memories 
by describing their sensory perceptions, behaviours, emo-
tions, physiological responses and cognitions during the 
traumatic event, in a safe environment and supported by 
their psychotherapist. Over several exposure sessions, ana-
logous to extinction learning, their initially strong, negative 
emotional response to the traumatic memories decreases. 
In recent years, technological advances made it possible to 
deliver TF-CBT via the internet. This helps to overcome 
emotional, social and practical barriers to care (Hoge et al., 
2004, 2014) and thereby, to reach an increasing number of 
individuals who would otherwise not commit to psy-
chotherapy. Meta-analytic research has proven that inter-
net-based and face-to-face TF-CBTs are equally effective 
(Kuester, Niemeyer, & Knaevelsrud, 2016).
Given that effective treatments for PTSD exist and 
innovative methods to disseminate them have been 
developed, it is a current challenge to better under-
stand the exact mechanisms of action underlying TF- 
CBT. By identifying its active ingredients, its efficacy 
and effectiveness can be further improved, accelerat-
ing remission and increasing response rates (Stojek, 
McSweeney, & Rauch, 2018). Therefore, it has been 
suggested to add measurements of biological corre-
lates of behaviours, cognitions or emotions of interest 
to clinical evaluations of TF-CBT (Fischer & Ehlert, 
2019; Yehuda et al., 2006). In this regard, two neu-
roanatomically closely related neuropeptides and hor-
mones, that is, oxytocin and arginine vasopressin, 
seem particularly interesting. Oxytocin has previously 
been related to a range of positive social behaviours 
in healthy humans, such as caring parenting beha-
viours (Feldman et al., 2011, 2012), trust (Kosfeld et 
al., 2005; Mikolajczak et al., 2010), cooperative com-
munication (Ditzen et al., 2009), or interpersonal 
closeness (Riem et al., 2019). In contrast, vasopressin 
has been associated with aggression (Coccaro, 
Kavoussi, Hauger, Cooper, & Ferris, 1998), decreased 
differentiation between neutral and threatening social 
stimuli (Thompson, Gupta, Miller, Mills, & Orr, 
2004) and increased physiological responses to threa-
tening social stimuli (Thompson, George, Walton, 
Orr, & Benson, 2006). Oxytocin’s and vasopressin’s 
involvement in social functioning already suggest 
their investigation as biomarkers of TF-CBT, as social 
factors contribute to PTSD development (Andrews, 
Brewin, & Rose, 2003; Brewin, Andrews, & Valentine, 
2000; Schumm, Briggs-Phillips, & Hobfoll, 2006; 
Shalev et al., 2019; Ozer et al. 2003) and a positive 
therapeutic relationship is a crucial basis for success-
ful TF-CBT (Cloitre, Stovall-McClough, Miranda, & 
Chemtob, 2004). Further, both neuropeptides influ-
ence fear and extinction learning, the neurocognitive 
processes underlying PTSD development and expo-
sure therapy. In this regard, oxytocin has often been 
associated with anxiolytic effects, whereas vasopres-
sin’s effects appear to be fear-promoting: In rats, 
central administration of synthetic oxytocin during 
fear conditioning decreased, whereas the same dose 
of vasopressin increased fear responses (Roozendaal 
et al., 1992). Further, post-conditioning central 
administration of oxytocin hexapeptide fragments 
decreased, while administration of vasopressin hexa-
peptide fragments increased fear recall (Stoehr, 
Cramer, & North, 1992). In healthy humans, intrana-
sal administration of oxytocin decreased fear 
responses during extinction acquisition and recall 
(Acheson et al., 2013; Eckstein et al., 2015), whereas 
animal studies indicated that high doses of centrally 
administered vasopressin delayed this process (Hayes 
& Chambers, 2005). However, it is worth noting that 
oxytocin’s and vasopressin’s effects on social func-
tioning and fear processing are not uniform, but 
instead strongly modulated by contextual and indivi-
dual factors (Roozendaal et al., 1992; Toth, Neumann, 
& Slattery, 2012; Olff et al., 2013).
Regarding the investigation of these neuropeptides 
in research on PTSD treatments, evidence is still scarce. 
Some studies evaluated the effects of a single intranasal 
oxytocin administration on selected functions that are 
impaired in PTSD (e.g. Koch et al., 2019; Nawijn et al., 
2016, 2017; Sack et al., 2017). One clinical trial investi-
gated the effects of repeated intranasal oxytocin admin-
istration in individuals with recent traumatic event 
exposure (van Zuiden et al., 2017) and a follow-up 
investigation of this trial also considered the role of 
blood oxytocin concentrations (Engel et al., 2020). 
Another clinical trial evaluated the effects of intranasal 
oxytocin as potential TF-CBT enhancer (Flanagan, 
Sippel, Wahlquist, Moran-Santa Maria, & Back, 2018). 
A follow-up investigation of this trial also investigated 
the role of blood oxytocin concentrations with regard to 
this intervention (Sippel, King, Wahlquist, & Flanagan, 
2020). The present study is the first one that included 
measurements of both, oxytocin and vasopressin into 
the clinical evaluation of TF-CBT.
1.1. Objectives
Specifically, this study aimed at answering three main 
scientific questions:
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First, we aimed at differentiating the impact of 
traumatic event exposure and PTSD on endogenous 
oxytocin and vasopressin concentrations. Therefore, 
we cross-sectionally compared oxytocin and vaso-
pressin between PTSD patients, healthy controls 
who were exposed to a deployment-related traumatic 
event and healthy controls who were never deployed. 
Previous evidence points towards pro-social and fear- 
reducing effects of oxytocin and indicates contrary 
effects of vasopressin. Therefore, is seems possible to 
expect higher oxytocin concentrations in individuals 
with fewer traumatic event-related strain, namely, the 
highest concentrations in the healthy controls who 
were never deployed, lower concentrations in the 
healthy controls who were exposed to a deployment- 
related traumatic event and the lowest concentrations 
in PTSD patients. Regarding vasopressin concentra-
tions, the opposite pattern can be expected.
Second, we aimed at exploring the associations of 
oxytocin and vasopressin with the severity of PTSD 
symptoms. Therefore, we tested whether these para-
meters were correlated in PTSD patients before onset 
of a 5-week, internet-based TF-CBT.
Third, we aimed at describing courses and inter-
actions between oxytocin, vasopressin and PTSD 
symptoms during an online psychotherapeutic inter-
vention. Therefore, we examined courses of these 
three parameters from pre- to post-treatment and 
3 months follow-up. We were particularly interested 
to explore whether oxytocin and vasopressin inter-
acted with PTSD symptoms over time.
2. Methods and materials
2.1. Participants
Participants were active and former service members 
of the German Armed Forces (n = 100). We initially 
intended to recruit female and male service members. 
However, given the significantly lower proportion of 
women in the German Armed Forces (approximately 
12%), which is even lower among deployed service 
members, it became evident that it was not possible 
to recruit a number of women that was sufficiently 
high for the purpose of this investigation, especially 
as additional factors such as menstrual cycle phase 
need to be considered in endocrine studies in women. 
Therefore, all participants in this study were male. 
Three groups were investigated: PTSD patients 
(n = 39; M = 37.74 years; SD = 9.62 years), deployed 
healthy controls (n = 33; M = 38.36 years; 
SD = 7.98 years) and non-deployed healthy controls 
(n = 28; M = 26.36 years; SD = 4.30 years). The group 
of PTSD patients consisted of service members who 
were treatment seeking for PTSD. Both healthy con-
trol groups did not fulfill criteria for PTSD or any 
other mental disorder, as confirmed by the German 
version of the Mini-International Neuropsychiatric 
Interview (Ackenheil et al., 1999; Sheehan et al., 
1998). The first healthy control group consisted of 
service members who were deployed abroad and 
reported a deployment-related traumatic event 
according to the DSM-5 criterion (American 
Psychiatric Association et al., 2013), as confirmed in 
a telephone screening interview and by the List of the 
Mental Health Advisory Team (Zimmermann et al., 
2014). The second healthy control group consisted of 
service members who were never deployed abroad 
and reported no traumatic event according to the 
DSM-5 criterion (American Psychiatric Association 
et al., 2013). General exclusion criteria that applied to 
all groups were acute psychosis, acute manic episode, 
current substance abuse or dependence, current sui-
cidal ideation, neurological disorder, acute somatic 
disease, concurrent psychotherapeutic treatment, or 
unstable psychotropic medication.
Participants were recruited via advertisements in 
military journals, on websites and in online chat 
rooms for service members. Printed flyers and posters 
were distributed in a number of health service centres 
and German Armed Forces Military Hospitals. 
Moreover, unit commanders distributed flyers in 
after-deployment seminars and the study was intro-
duced to military psychologists and psychiatrists at 
German Armed Forces mental health conferences.
2.2. Study design
This study is part of a randomized waitlist-controlled 
trial investigating the feasibility, acceptability and 
efficacy of a 5-week internet-based TF-CBT in 
German Armed Forces service members (Niemeyer 
et al., 2020). The study design is explained and illu-
strated in Table 1. The intervention was based on the 
treatment protocols of Interapy (Lange et al., 2003) 
and Integrative Testimonial Therapy (Knaevelsrud, 
Böttche, Pietrzak, Freyberger, & Kuwert, 2017) and 
adapted to the military context. The model treatment 
protocols have been proven effective in reducing 
PTSD symptoms in diverse samples with large effect 
sizes (Hedges’s g = 0.81; CI = 0.62–1.00], Kuester, 
Niemeyer, & Knaevelsrud, 2016). Our protocol 
encompassed 10 modules of writing assignments 
completed by the PTSD patients for which they 
received written feedback by the therapists. The con-
tact between PTSD patients and therapists was lim-
ited to the 10 texts that the patients wrote in 
accordance with the writing assignments and the 8 
feedback letters written by the therapists (no feedback 
was provided after sessions 2 and 5). The therapist 
feedback was based on standardized templates from 
the treatment manual which were adapted to the 
patient’s specific needs. The intervention was struc-
tured in three treatment phases: biographical 
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reconstruction, exposure and cognitive restructuring. 
During biographical reconstruction, patients reflected 
on their previous life experiences from childhood up 
to the traumatic event. They described positive 
experiences, as well as difficult ones that they had 
successfully handled. Then, psychoeducational texts 
by the therapists prepared the patients for the expo-
sure sessions in which patients repeatedly described 
the worst traumatic event they had experienced. They 
were instructed to write in the first person and the 
present tense as well as to describe the most painful 
aspects, emotions, and sensory impressions. The sub-
sequent treatment phase of cognitive restructuring 
aimed at developing a new perspective on the trau-
matic event. Patients were instructed to reflect on 
feelings such as guilt and shame, to question dysfunc-
tional patterns in their thoughts and behaviours, to 
correct unrealistic assumptions, to consider possible 
positive consequences of the traumatic event, and to 
plan how they wanted to deal with such things in the
Table 1. Overview of assessments, flow of participants and available data.
Assessments
Deployed healthy controls - - -
Non-deployed healthy controls - - -
PTSD patients, waitlist condition




n (deployed healthy controls) 0 33 0 0 0 0 0 0 0 0 0 0 0 0
n (non-deployed healthy 
controls)
0 28 0 0 0 0 0 0 0 0 0 0 0 0
n (PTSD patients, waitlist 
condition)
19 17 17 16 16 13 13 13 13 13 13 13 13 12
n (PTSD patients, non-waitlist 
condition)
0 20 14 13 12 9 9 9 8 8 8 8 8 7
Available data
CAPS-5
n (deployed healthy controls) 0 33 0 0
n (non-deployed healthy 
controls)
0 0 0 0
n (PTSD patients, waitlist 
condition)
19 17 13 12
n (PTSD patients, non-waitlist 
condition)
0 20 8 7
Oxytocin
n (deployed healthy controls) 0 33 0 0
n (non-deployed healthy 
controls)
0 261 0 0
n (PTSD patients, waitlist 
condition)
19 17 122 112
n (PTSD patients, non-waitlist 
condition)
0 182,3 8 7
Vasopressin
n (deployed healthy controls) 0 33 0 0
n (non-deployed healthy 
controls)
0 28 0 0
n (PTSD patients, waitlist 
condition)
19 17 13 12
n (PTSD patients, non-waitlist 
condition)
0 193 8 7
Note. 1 Data from two participants were defined as outliers and therefore removed. 2 Data from one participant was defined as outlier and therefore 
removed. 3 Data from one participant is missing as assessment was cancelled before blood sampling. M = module; CAPS-5 = Clinician-Administered 
PTSD Scale for DSM-5; = Assessment was conducted in the respective group. – = Assessment was not conducted in the respective group. 
The rows representing assessments show when and how often posttraumatic stress disorder (PTSD) symptoms, oxytocin and vasopressin were assessed 
in the respective groups. Deployed and non-deployed healthy controls were assessed at one timepoint and did not receive the internet-based trauma- 
focused cognitive behavioural treatment. PTSD patients who were randomly assigned to the waitlist condition were assessed at four timepoints: once 
before a 6-week waiting period (TX), as well as pre-treatment (T1), post-treatment (T2) and at follow-up (T3). PTSD patients who were randomly 
assigned to the non-waitlist condition were assessed at three timepoints: T1, T2 and T3. The rows representing flow of participants show the number 
of participants assessed per group and timepoint. They also depict study and therapy dropout. The rows representing available data show the number 
of available data for our outcomes of interest per group and timepoint. PTSD symptoms were not assessed in non-deployed healthy controls. For 
cross-sectional baseline comparisons, variables of participants’ respective first assessments were compared. TX was the first assessment for PTSD 
patients assigned to waitlist condition and T1 was the first assessment for PTSD patients assigned to non-waitlist condition and both healthy control 
groups. For longitudinal analyses, PTSD patients’ T1, T2 and T3 data were used. This implies that data from PTSD patients assigned to waitlist- and 
non-waitlist condition were combined. 
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future. For an even more detailed description of the 
treatment manual (Niemeyer et al., 2020).
Before assignment to the trial, PTSD patients 
were – based on a computer-generated randomiza-
tion list – assigned to the waitlist or non-waitlist 
condition. Patients in the waitlist condition waited 
for six weeks before starting treatment, patients in the 
non-waitlist condition started treatment immedi-
ately. Patients in the waitlist condition completed 
four assessments at the German Armed Forces 
Military Hospital Berlin, in which psychological and 
biological data was collected: a pre-waiting, pre- 
treatment, post-treatment and follow-up assessment. 
Patients in the non-waitlist condition completed 
three assessments: pre-treatment, post-treatment 
and follow-up. Healthy controls completed one 
assessment.
In order to address our first scientific question, that 
is, cross-sectional group comparisons, data of each 
group’s respective first assessment was used. For the 
purpose of the second and third scientific question, 
that is, the investigation of interactions between PTSD 
symptoms and endocrine parameters in relation to the 
internet-based TF-CBT, PTSD patients’ pre-treatment, 
post-treatment and follow-up data was used. Data was 
collected between July 2016 and July 2018.
The study was pre-registered in the Australian 
Clinical Trials Registry (ACTRN 12,616,000,956,404). 
After internal approval by the German Armed Forces, 
the study was approved by the Ethics committee of 
Freie Universität Berlin (reference number: 85/2014; 
addendum: 116/2016).
2.3. Psychological assessments
The German translation of the Clinician Administered 
PTSD Scale for DSM-5 (CAPS-5; Weathers et al. 2018) 
was used to assess PTSD symptoms and diagnosis. The 
CAPS-5 measures PTSD symptoms in the four 
domains: re-experiencing symptoms, avoidance symp-
toms, negative alterations in cognition and mood and 
alterations in arousal and reactivity. By means of 
a standardized interview with the patient, a clinician 
(a trained master’s level or a PhD student) rated the 
severity of symptoms experienced during the last 
month on a 5-point scale ranging from 0 = not present 
to 4 = extreme.
2.4. Biological assessments
2.4.1. Sampling and biochemical analyses
Endogenous oxytocin and vasopressin concentrations 
were measured in blood. At 8 a.m. on the first day of 
assessment in the case of a single-day assessment or 
on the second day in the case of a two-days assess-
ment, participants were invited to the laboratory. 
Across all samples, there were no significant 
differences in oxytocin (F1,142 = 0.00, p = .96) or 
vasopressin concentrations (F1,147 = 0.78, p = .09) 
between participants with single day versus two days 
assessments.
Time of blood sampling was recorded and we 
observed high compliance to the protocol: In 83.33%, 
blood was drawn exactly at 8 a.m. Deviations were 
M = 3.00 SD = 10.00 [0.00; 75.00] minutes. Patients 
were instructed not to eat, drink (except for water), 
consume caffeine or nicotine before sampling. 
Compliance to these instructions was reported by the 
patients in 91.67% of the samples (143 samples, eat), 
96.79% (151 samples, drink), 89.10% (139 samples, 
caffeine) and 79.49% (124 samples, nicotine), respec-
tively. Furthermore, age, body weight, body height, and 
leucocytes were assessed. In 96.15% of the samples (150 
samples), leucocyte values were within the normal 
range, 1.92% (3 samples) were considered as too low, 
0.61% (1 sample) as too high and for 1.21% (2 samples), 
leucocyte values were unavailable.
Blood was collected in 9.00 ml serum tubes (Sarstedt, 
Germany). After sampling, tubes were softly shaken, 
then put aside for 30 minutes, protected from light, in 
order to allow blood to plot. Then, tubes were centri-
fuged at 1000xg for 10 minutes and serum was pipetted 
into smaller, 1.50 ml tubes (Eppendorf, Germany). 
Samples were stored in a freezer at −80°C. After com-
pletion of data collection, all samples were sent to the 
cooperating laboratory. They were extracted and ana-
lysed using a highly sensitive and selective RIA 
(RIAgnosis, Regensburg, Germany), as described in 
(Landgraf, Neumann, Holsboer, & Pittman, 1995) and 
in (Landgraf & Neumann, 2004). All samples were 
measured within the same assay, in order to avoid inter- 
assay variability. Intra-assay variability was < 10%. The 
detection limit was 0.1–0.5 pg/ml for both oxytocin and 
vasopressin, depending on the age of the tracers. No 
sample was below the detection limit. There was no 
significant cross-reactivity with structurally related pep-
tides including the ring hexapeptides and the terminal 
tripeptides of oxytocin and vasopressin.
2.4.2. Preparation of biological data
Visual inspection and descriptive statistics revealed 
that oxytocin data was not normally distributed 
(M = 4.50 pg/ml; SD = 1.88 [1.77; 13.90]; skew-
ness: 2.76; curtosis: 9.93). Five outliers were identi-
fied, deviating more than 3 SD from M. Outlier 
removal and log-transformation (LG10(1+ oxytocin)) 
resulted in normally distributed data that was used 
for analyses (M = 0.71; SD = 0.09 [0.44; 1.04]; skew-
ness: 0.19; curtosis: 0.55). With regard to vasopressin, 
visual inspection and descriptive statistics revealed 
normally distributed data and no outliers 
(M = 3.50 pg/ml; SD = 0.53 [2.22; 5.01]; skew-
ness: 0.02; curtosis: −0.72). Accordingly, complete 
and non-transformed data was used for analyses.
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2.5. Statistical analyses
2.5.1. Group differences in endocrine parameters
For cross-sectional group comparisons, we conducted 
two one-way ANOVAs, using group (PTSD patients 
vs. deployed healthy controls vs. non-deployed 
healthy controls) as factor and oxytocin and vaso-
pressin as outcomes.
2.6. Correlations before internet-based 
trauma-focused cognitive behavioural treatment 
(TF-CBT) onset
We used Pearson’s coefficient r to correlate pre- 
treatment oxytocin, vasopressin and PTSD symptoms 
(total CAPS-5 scores).
2.6.1. Courses of endocrine parameters and PTSD 
symptoms
In order to describe courses of oxytocin, vasopressin 
and PTSD symptoms, we performed three repeated- 
measures ANOVAs from pre-treatment over post- 
treatment to follow-up assessments. Time was used 
as within-factor, while oxytocin, vasopressin and 
PTSD symptoms were used as the respective out-
comes. As both PTSD patient groups (waitlist and 
non-waitlist condition) were collapsed for longitudi-
nal analyses, there was no between-factor.
2.6.2. Interactions of endocrine parameters with 
PTSD symptoms over time
In order to explore interactions between oxytocin and 
vasopressin with PTSD symptoms over time, we 
tested whether pre-treatment values of one parameter 
were correlated with post-treatment values of another 
parameter. In addition, we tested whether post- 
treatment values of one parameter were correlated 
with follow-up values of another parameter. 
Moreover, we created change scores, indicating an 
increase (positive value) or a decrease (negative 
value) in oxytocin, vasopressin or PTSD symptoms 
from one assessment to the next. We tested whether 
pre- and post-treatment values of one parameter were 
correlated with change scores from pre- to post- 
treatment or from post-treatment to follow-up in 
another parameter. Vice versa, we explored whether 
change scores from pre-to post-treatment and from 
post-treatment to follow up in one parameter were 
correlated with post- or follow-up values of another 
parameter.
Concerning the analyses in the context of the 
internet-based TF-CBT, all results that are presented 
in the manuscript are based on data of those PTSD 
patients with available PTSD symptoms, oxytocin and 
vasopressin data at pre-treatment, post-treatment and 
follow-up (complete cases, n = 16). This compara-
tively low number of cases is mainly due to the high 
dropout rate (as explained in Niemeyer et al., 2020). 
In order to test the robustness of our results, descrip-
tive and correlational analyses were also conducted in 
all cases with available data in the respective para-
meter per assessment (n = 17–37). Results were com-
pared and no significant differences were found. An 
overview of longitudinal PTSD symptoms, oxytocin 
and vasopressin data, as well as their longitudinal 
correlations and correlations with change scores is 
given in supplementary material 1 and 2, for all and 
complete cases, respectively.
Non-adjusted α was defined as .05. All analyses 
were performed with SPSS Statistics, version 
25 (IBM).
3. Results
3.1. Flow of participants
The number of participants and available data for our 
outcomes of interest are illustrated in Table 1. 
Baseline demographic, trauma-related and psycholo-
gical variables are presented in Table 2. It reveals 
group differences in age: Non-deployed healthy con-
trols were younger than PTSD patients and deployed 
healthy controls. As deployment is a common event 
in most military careers, service members are non- 
(or not yet-)deployed only at early career stages and 
thus, at younger age. Except for age, no demographic 
group differences were detected.
Concerning deployment-related traumatic event 
exposure, in PTSD patients, having seen destroyed 
houses or villages (n = 33, 84.62%), knowing some-
one seriously injured or killed (n = 29, 74.36%) and 
having seen (parts of) dead bodies (n = 28, 71.79%) 
were the most frequently reported potentially trau-
matic events, according to the List of the Mental 
Health Advisory Team (Zimmermann et al., 2014). 
In deployed healthy controls, having seen destroyed 
houses or villages (n = 26, 78.79%), having experi-
enced hostility by civilians (n = 20, 60.61%) and 
having seen (parts of) dead bodies (n = 19, 57.58%) 
were the most frequently reported potentially trau-
matic events. As Table 2 shows, PTSD patients and 
deployed healthy controls did not differ with regard 
to deployment-related variables, but as expected, they 
differed with regard to PTSD symptoms.
3.2. Group differences in endocrine parameters
The cross-sectional group comparison did not reveal 
any differences in endogenous oxytocin or vasopressin 
concentrations between PTSD patients, deployed 
healthy controls or non-deployed healthy controls (see 
Table 2 and Figure 1), although the analyses were ade-
quately powered to detect a medium-sized effect 
(f = .32, α = .05; 1-β = .80).
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Two non-deployed healthy controls reported suf-
fering from chronic somatic diseases that might have 
an impact on their endocrine states. Therefore, we 
repeated the cross-sectional group comparisons with-
out these two individuals Again, groups did not sig-
nificantly differ in oxytocin (F (2, 91) = 1.67, p = .19) 
or vasopressin concentrations (F (2, 94) = 0.06, p = .94)
3.3. Correlations before internet-based TF-CBT 
onset
PTSD symptoms were neither correlated with oxyto-
cin (r = -.19, p = .47), nor with vasopressin (r = .11, 
p = .68) before onset of the internet-based TF-CBT. 
Likewise, in completers, no correlations of oxytocin 
and vasopressin with PTSD symptoms were detected 
at post-treatment or follow-up assessment (see sup-
plementary material 2).
3.4. Courses of endocrine parameters and PTSD 
symptoms
Courses of PTSD symptoms, oxytocin and vasopressin 
are illustrated in Figure 2. In those patients who com-
pleted the TF-CBT, there was no change in mean PTSD 
symptoms from pre- to post-treatment and follow-up 
(F2, 30 = 1.00, p = .38). PTSD symptoms remained stable 
within individuals (pre- to post-treatment: r = .83, 
p < .01, post-treatment to follow-up: r = .93, p < .01). 
In completers, mean oxytocin did not change from pre- 
to post-treatment and follow-up (F2, 30 = 1.41, p = .26) 
and oxytocin was not stable within individuals over
Table 2. Baseline comparisons of demographic, posttraumatic stress disorder (PTSD) symptom-related and endocrine variables.
PTSD patients 
(n = 39)
Deployed healthy controls 
(n = 33)
Non-deployed healthy controls 
(n = 28) Statistics
Demographic information
Age 37.74 (9.62)a 38.36 (7.98) 26.36 (4.30) F (2, 96) = 22.09, p < .01
BMI 26.84 (3.06)a 26.55 (3.06)a 25.54 (2.42) F (2, 91) = 1.77, p = .18
Number of cigarettes per day 0.94 (1.12)a 0.42 (0.75) 0.55 (0.96)a F (2, 88) = 2.72, p = .07
Number of deployments 2.84 (3.05)a 3.21 (2.76) - F (1, 69) = 0.28, p = .60
Total number of days deployed 357.03 (369.94)a 415.31 (574.40)a - F (1, 66) = 0.27, p = .60
PTSD symptoms
PTSD diagnosis (n, %) 25, 64.10 0, 0.00 -
Overall symptoms 35.05 (14.71) 1.88 (4.08) - F (1, 70) = 157.19, p < .01
Re-experiencing symptoms 9.87 (4.32) 0.36 (1.11) - F (1, 70) = 150.83, p < .01
Avoidance symptoms 3.92 (2.07) 0.18 (0.72) - F (1, 70) = 97.43, p < .01
Negative alterations in cognition 
and mood
11.13 (6.04) 0.18 (0.53) - F (1, 70) = 107.61, p < .01
Alterations in arousal and 
reactivity
10.13 (4.34) 1.15 (2.42) - F (1, 70) = 111.71, p < .01
Endocrine parameters
Oxytocin log (pg/ml) 0.72 (0.10)a 0.74 (0.09) 0.68 (0.12)a F (2, 93) = 2.32, p = .10
Vasopressin pg/ml 3.55 (0.60)a 3.52 (0.48) 3.54 (0.63) F (2, 96) = 0.05, p = .95
Note. a Due to missing values, information was not available for all participants (see also Table 1 for main outcomes). If not indicated differently, 
descriptive information is presented as M (SD) and comparisons were conducted based on one-way ANOVAs (in order to compare PTSD patients, 
deployed healthy controls and non-deployed healthy controls) or t-tests (in order to compare PTSD patients and deployed healthy controls). All PTSD 
symptom-related variables are based on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). 
Figure 1. Endogenous oxytocin and vasopressin concentrations in posttraumatic stress disorder (PTSD) patients, deployed 
healthy controls and non-deployed healthy controls, as assessed at the participants’ first assessments. No significant group 
differences were detected. M and SD of log-transformed oxytocin and non-transformed vasopressin concentrations are shown.
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time (pre- to post-treatment: r = .04, p = .89, post- 
treatment to follow-up: r = .19, p ≤ .47). Likewise, in 
completers, there was no change in mean vasopressin 
from pre- to post-treatment and follow-up (F2, 30 
= 1.24, p = .28) and it was not stable within individuals 
over time (pre- to post-treatment: r = .44, p = .08, post- 
treatment to follow-up: r = .01, p = .98).
3.5. Interactions of endocrine parameters with 
PTSD symptoms over time
In completers, oxytocin and vasopressin, as assessed 
pre-treatment, were not correlated with PTSD symp-
toms post-treatment (oxytocin: r = –.25, p = .35, 
vasopressin: r = .27, p = .32). Likewise, pre- 
treatment oxytocin and vasopressin did not predict 
changes in PTSD symptoms from pre- to post- 
treatment (oxytocin: r = –.07, p = .79, vasopressin: 
r = .25, p = .36). Oxytocin and vasopressin post- 
treatment were not correlated with PTSD symptoms 
at follow-up (oxytocin: r = .24, p = .36, vasopressin: 
r = .13, p = .62), nor were they correlated with the 
change score of PTSD symptoms from post- 
treatment to follow-up (oxytocin: r = .44, p = .08, 
vasopressin: r = .04, p = .89).
Vice versa, in completers, PTSD symptoms pre- 
treatment were neither correlated with oxytocin and 
vasopressin, as assessed post-treatment (oxytocin: 
r = .12, p = .64, vasopressin: r = .22, p = .41), nor 
were they correlated with changes in oxytocin and 
vasopressin from pre- to post-treatment (oxytocin: 
r = .23, p = .38, vasopressin: r = .08, p = .77). 
Likewise, PTSD symptoms, as assessed post- 
treatment were not correlated with oxytocin and 
vasopressin, as measured at follow up (oxytocin: 
r = –.09, p = .73, vasopressin: r = –.18, p = .63) and 
they were not correlated with their change scores 
from post-treatment to follow-up (oxytocin: 
r = –.13, p = .62, vasopressin: r = –.23, p = .39).
4. Discussion
4.1. Summary of evidence
Our findings suggest that endogenous oxytocin and 
vasopressin concentrations are unrelated to PTSD 
psychopathology in patients who completed an inter-
net-based TF-CBT. We did not detect any difference 
in these endocrine parameters between PTSD 
patients, deployed and non-deployed healthy con-
trols. Furthermore, in patients, oxytocin and vaso-
pressin were not correlated with PTSD symptoms 
when measured simultaneously. This is in line with 
both, previous meta-analytic evidence on cross- 
sectional associations between these parameters 
(Engel et al., 2019) as well as with the results from 
previous clinical trials. In the trial that evaluated 
repeated intranasal oxytocin administration as PTSD 
prevention (van Zuiden et al., 2017), blood oxytocin 
concentrations were neither prognostic biomarkers 
for PTSD symptom development, nor prescriptive 
biomarkers of the intervention’s effectiveness (Engel 
et al., 2020). Likewise, in the clinical trial that inves-
tigated the role of blood oxytocin concentrations in 
a prolonged exposure intervention that was augmen-
ted by intranasal oxytocin administration (Flanagan 
et al., 2018), these concentrations were not correlated 
with PTSD symptoms before intervention onset, nor 
did they correspond with symptom changes (Sippel 
et al., 2020).
Besides evaluating clinical treatment effects, we 
investigated oxytocin and vasopressin as possible bio-
markers of internet-based TF-CBT, in order to 
explore treatment effects on a biological level. Our 
results showed that neither PTSD symptoms, nor 
oxytocin or vasopressin changed during internet- 
based TF-CBT or to follow-up in those patients who 
completed the TF-CBT. Notably, while PTSD symp-
toms were stable within individuals, the endocrine 
parameters were not. Our exploratory investigations 
revealed that oxytocin and vasopressin did not
Figure 2. Courses of posttraumatic stress disorder (PTSD) severity (total Clinician-Administered PTSD Scale for DSM-5 scores), 
oxytocin (log-transformed pg/ml) and vasopressin (pg/ml) from pre-treatment to post-treatment and follow up in all PTSD 
patients with complete available data (n = 16). There was no significant mean change in any of the outcomes. PTSD severity 
remained stable within individuals, whereas oxytocin and vasopressin were not correlated within individuals over time.
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predict PTSD symptoms longitudinally and likewise, 
PTSD symptoms were not associated with the endo-
crine parameters longitudinally.
4.2. Interpretation of results
In this study, we used single measurements of oxyto-
cin and vasopressin and yielded unsatisfactory 
intraindividual stability. A prerequisite to use biolo-
gical measurements as biomarkers for mental disor-
ders during psychotherapeutic or pharmacological 
interventions is the possibility to measure these para-
meters repeatedly. Only then can potential changes in 
biological measurements clearly be related to the 
intervention effect. Our study showed that this pre-
requisite is not given when measuring oxytocin and 
vasopressin only once, even though this is the most 
frequently applied approach for these neuropeptides 
in PTSD research (Engel et al., 2019).
These problems have been discussed previously. The 
discussions mainly focused on two critical aspects, namely, 
the open question to which extent endogenous oxytocin 
and vasopressin concentrations can reflect central pro-
cesses and the diverging approaches to the biochemical 
analysis of oxytocin and vasopressin. Oxytocin and vaso-
pressin are synthesized in magnocellular neurons of the 
supraoptic and paraventricular nuclei of the hypothalamus 
(Brownstein, Russell, & Gainer, 1980). Their first distribu-
tion pathway involves direct axonal projections to their 
central target regions. Importantly, oxytocin and vasopres-
sin exert their psychological effects through this first dis-
tribution pathway (Brownstein, Russell, & Gainer, 1980; 
Landgraf & Neumann, 2004). The second distribution 
pathway involves paracrine oxytocin and vasopressin 
release into the cerebrospinal fluid (Pow & Morris, 1989). 
The third distribution pathway is often referred to as the 
hypothalamo-neurohypophysial system (Brownstein, 
Russell, & Gainer, 1980; Neumann, 2008): Following axo-
nal oxytocin and vasopressin transport from the hypotha-
lamic nuclei to the pituitary gland, these peptides are 
released into the peripheral circulation. Accordingly, 
their concentrations can be measured in peripheral tissues, 
such as blood. To date, it remains a matter of ongoing 
debate whether or how the three distribution pathways 
interdepend and accordingly, to which extent peripheral 
oxytocin and vasopressin concentrations can reflect central 
processes. A meta-analysis showed that under basal con-
ditions, central and peripheral oxytocin concentrations 
were unrelated, but that they were positively associated 
when measured after stress exposure or after intranasal 
oxytocin administration (Valstad et al., 2017). This indi-
cates that oxytocin’s central actions are to some extent 
reflected in peripheral concentrations, albeit the exact 
underlying mechanisms and temporal dynamics clearly 
need further investigation.
Concerning the biochemical analysis, the large 
range of reported oxytocin and vasopressin values 
resulting from analyses of extracted versus unex-
tracted samples has stimulated debates (Leng & 
Sabatier, 2016). A meta-analysis showed that 
reported oxytocin concentrations were excessively 
higher when measured in unextracted versus in 
extracted blood samples (275.61 pg/ml versus 
4.75 pg/ml; Engel et al., 2019). As a consequence, 
measurements of oxytocin concentrations in unex-
tracted blood samples have been criticized for being 
invalid (Szeto et al., 2011), while other researchers 
pointed out that the different analysis methods might 
correspond with different states of oxytocin 
(MacLean et al., 2019). In the present study, oxytocin 
and vasopressin concentrations were analysed with 
a well-established RIA (RIAgnosis, Regensburg, 
Germany) that has been developed by leading 
researchers in the field with many years of experience 
(Neumann & Landgraf, 2019). Mean oxytocin con-
centrations of 4.50 pg/ml, as they were observed in 
our study, were comparable with the mean values 
reported in other studies that measured oxytocin 
concentrations in extracted blood samples (Engel 
et al., 2019).
Even though we relied on a valid measurement 
approach, the exact factors that caused the observed 
low intraindividual stability remain unclear. 
Oxytocin concentrations tend to increase in response 
to emotional (Barraza & Zak, 2009) and physical 
stimulation (Bello, White-Traut, Schwertz, 
Pournajafi-Nazarloo, & Carter, 2008) but interest-
ingly, in the latter study, increases in these concen-
trations were also observed in the passive control 
condition, confirming a generally low intraindividual 
stability. This highlights the need to establish 
advanced parameters that provide stable indicators 
of oxytocin and vasopressin functioning. This might 
be achieved by increasing the number of measure-
ments and merging them into more conclusive sta-
tistical parameters such as the area under the curve 
(Pruessner, Kirschbaum, Meinlschmid, & 
Hellhammer, 2003). Furthermore, confounders of 
oxytocin and vasopressin need to be controlled for 
(Engel et al., 2019). In the present study, blood sam-
pling was highly standardized, by scheduling it at 
a precise time and providing precise instructions 
with regard to behaviours before measurements. 
Further, our sample was comparatively homoge-
neous, as it included only men with the same profes-
sion. Especially amidst the low intraindividual 
stability of both endocrine parameters, it remains 
unclear which factors actually determined the 
observed values. Our study’s results indicate that the 
values were not determined by traumatic event 
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exposure, PTSD symptoms, sex, profession, time 
of day and behaviours before measurement, but it 
remains unresolved which factors actually influenced 
them.
Despite a strong theoretical rationale to investigate 
oxytocin and vasopressin as biomarkers of TF-CBT, 
which has been derived from animal studies and experi-
mental studies in humans, the transfer to the clinical 
setting did not succeed. Besides their involvement in 
social functioning and fear processing, oxytocin and 
vasopressin are involved in a variety of other physiologi-
cal, behavioural and psychological functions (for over-
views, see Boll et al., 2018; Donaldson & Young, 2008; 
Gimpl & Fahrenholz, 2001; Lawson 2017; Macdonald & 
Feifel, 2014; Macdonald & MacDonald, 2010; Winter & 
Jurek, 2019; Yang et al., 2013). It appears that experi-
mental paradigms that specifically target either social 
functioning or fear processing might be more appropri-
ate to investigate oxytocin or vasopressin as potential 
underpinnings of psychopathological functions in 
a more hypothesis-driven manner. Alternatively, with 
regard to psychotherapy, oxytocin and vasopressin 
might be measured repeatedly within single sessions, 
such as exposure sessions. Moving from the macro- to 
the micro-level of psychotherapy evaluation research 
might be more helpful to identify the active ingredients 
of TF-CBT.
4.3. Limitations
Contrasting previous findings (Kuester et al., 2016), 
the internet-based TF-CBT evaluated in the present 
study was not effective in reducing PTSD symptoms 
(Niemeyer et al., 2020). The limited number of PTSD 
patients who started and completed therapy impeded 
a differential investigation of therapy effectiveness 
compared with a waiting period. However, as mer-
ging all patients into one group in order to quantify 
changes during the internet-based TF-CBT and fol-
low-up period did not result in any effects, it was not 
necessary to compare these null-effects with a passive 
condition, anyway. Still, in general, an effective treat-
ment is necessary to identify its active ingredients, 
and this prerequisite was not given here. The small 
number of patients observed limits the informative 
value of the observed null-findings on both, clinical 
and endocrine parameters. However, the results of 
the present study remained stable when using all 
values instead of those of completers only, which 
indicates that the findings are still plausible.
Concerning the cross-sectional group compari-
sons, as non-deployed healthy controls were signifi-
cantly younger than the deployed healthy controls 
and PTSD patients, and as their younger age is 
a characteristic that is systematically related to their 
status, we cannot fully exclude the possibility that age 
as a confounding variable suppressed the emergence 
of potential group differences. However, it is worth 
noting that neither oxytocin (r = –.03, p = .69), nor 
vasopressin (r = .03, p = .70) concentrations were 
significantly correlated with age across all samples.
5. Conclusion
In the present investigation, oxytocin and vasopressin 
were not informative biomarkers of traumatic event 
exposure, PTSD symptoms or TF-CBT. Previous evi-
dence from animal studies and non-clinical samples 
indicated that they were involved in social functioning 
and fear processing, two functions that are important in 
PTSD development and treatment. However, the infor-
mative value of single measurements of oxytocin and 
vasopressin was restricted, mainly due to the low 
intraindividual stability of these parameters. More 
basic research is needed in order to identify parameters 
of the endogenous oxytocin and vasopressin system that 
are more stable and less sensitive to physiological con-
founders. Only then can oxytocin and vasopressin suc-
cessfully be implemented into the clinical evaluation of 
TF-CBT.
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